GABRA2 and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: These findings validate Gabra2 as a genetic modifier of Dravet syndrome, and support enhancing function of α2-containing GABAA receptors as treatment strategy for Dravet syndrome.